Premium
In vivo targeting of Hodgkin and Reed‐Sternberg cells of Hodgkin's disease with monoclonal antibody Ber‐H2 (CD30): immimohistological evidence
Author(s) -
Falini B.,
Flenghi L.,
Fedeli L.,
Broe M. K.,
Bonino C.,
Stein H.,
Düurkop H.,
Bigerna B.,
Barbabietola G.,
Venturi S.,
Aversa F.,
Pizzolo G.,
Bartoli A.,
Pileri S.,
Sabattini E.,
And R. Palumbo,
Martelli M. F.
Publication year - 1992
Publication title -
british journal of haematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.907
H-Index - 186
eISSN - 1365-2141
pISSN - 0007-1048
DOI - 10.1111/j.1365-2141.1992.tb04591.x
Subject(s) - immunoscintigraphy , in vivo , monoclonal antibody , antibody , antigen , microbiology and biotechnology , cd30 , pathology , cancer research , medicine , chemistry , immunohistochemistry , immunology , biology , radioimmunotherapy
Summary The ability of the Ber‐H2 (CD30) monoclonal antibody (mAb) to target in vivo Hodgkin (H) and Reed‐Sternberg (R‐S) cells was investigated in six patients with advanced Hodgkin's disease (HD). The patients were injected with scaled‐up quantities of‘cold’Ber‐H2 mixed‐up to a small dose of 131 I‐labelled Ber‐H2. and in vivo binding of the antibody to H and R‐S cells was assessed by immunohistologi‐cal analysis of tumour biopsies and immunoscintigraphy. Only 50% of tumour sites were imaged at scintigraphy by the 131 I‐labelled Ber‐H2. In contrast, immunohistological studies on tissue biopsies, taken 24–72 h following the mAb injection, showed that H and R‐S cells in all tumour sites, including those that were not imaged by immunoscintigraphy, were specifically and strongly labelled in vivo by the injected Ber‐H2, at a dose as low as 30–50 mg of antibody. In vivo binding of a single dose of Ber‐H2 mAb to H and R‐S cells did not result in any anti‐tumour effect. The excellent in vivo targeting of H and R‐S cells with the Ber‐H2 mAb may have been the result of multiple favourable factors, including: (a) the restricted expression of the CD30 antigen in normal human tissues; (b) the low level of soluble CD30 in the serum of our patients; and (c) the high affinity of the Ber‐H2 mAb for the CD30 molecule. The immunohistological results presented in this study provide a strong argument for using the Ber‐H2 mAb as a carrier for delivering cytotoxic agents (isotopes or toxins) to neoplastic cells of HD refractory to conventional therapy.